Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression
BACKGROUND Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Con...
Gespeichert in:
Veröffentlicht in: | The Prostate 2000-09, Vol.44 (4), p.265-270 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 270 |
---|---|
container_issue | 4 |
container_start_page | 265 |
container_title | The Prostate |
container_volume | 44 |
creator | Dawkins, Hugh J.S. Sellner, Loryn N. Turbett, Gavin R. Thompson, Colin A. Redmond, Sharon L. McNeal, John E. Cohen, Ronald J. |
description | BACKGROUND
Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression.
METHODS
IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer.
RESULTS
LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual.
CONCLUSIONS
Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/1097-0045(20000901)44:4<265::AID-PROS1>3.0.CO;2-I |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71764963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71764963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4901-fce52775fc2b9d0e906e09fa32b7a638598412119aedaacebaddc400f79a1d333</originalsourceid><addsrcrecordid>eNqVkt9u0zAUhyMEYmXwCsgXCHXSUmzHiZuCkKYURqSydgzE5ZHrnLSG_ClxstHn4gVxSClccINvIjm_851jf_a8mNEJo5S_YDSWPqUiHHPqVkzZmRAz8YpH4Wx2kc791YflDXsdTOgkWb7kfnrPGx1r7nsjyiX1BQvkiffI2i-UOirlD70TFwqZmMYj78fc2NZUujV1RdbY3iFWxFRto7JOt6ogWjXaVHWpSJ2Tdotk19S2VS2ScTpP_NXZOdmazdbfuAok2d7uCmWNIuNVeuX-qSpzuFu3dXssNZq4bFUf0eeks6bakLIuUHeFakipmq_Y2L6nVpXGpq_dNGitm_Ox9yBXhcUnh--p9-ntm4_JO3-xvEyTi4WvhbsqP9cYcinDXPN1nFGMaYQ0zlXA11JFwTSMp4JxxmKFmVIa1yrLtKA0l7FiWRAEp97zget6f-vQtlAaq7EoVIV1Z0EyGYk46oPXQ1C7A9oGc9g1xh1hD4xCbxJ6K9Bbgd8mQQgQ4EwCOJPwyyQEQCFZAofUMZ8emnfrErO_iIM6F3h2CCirVZE37p6M_ZMTkk4j5mI3Q-zOFLj_r8H-Ndew4aj-QHWvB78fqc4aRDKQIXy-uoTrKJA8iRbwPvgJutvV9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71764963</pqid></control><display><type>article</type><title>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Dawkins, Hugh J.S. ; Sellner, Loryn N. ; Turbett, Gavin R. ; Thompson, Colin A. ; Redmond, Sharon L. ; McNeal, John E. ; Cohen, Ronald J.</creator><creatorcontrib>Dawkins, Hugh J.S. ; Sellner, Loryn N. ; Turbett, Gavin R. ; Thompson, Colin A. ; Redmond, Sharon L. ; McNeal, John E. ; Cohen, Ronald J.</creatorcontrib><description>BACKGROUND
Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression.
METHODS
IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer.
RESULTS
LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual.
CONCLUSIONS
Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/1097-0045(20000901)44:4<265::AID-PROS1>3.0.CO;2-I</identifier><identifier>PMID: 10951489</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Alleles ; Biological and medical sciences ; cancer progression ; Carcinoma, Intraductal, Noninfiltrating - genetics ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Carcinoma, Intraductal, Noninfiltrating - surgery ; Disease Progression ; dysplasia ; Genetic Markers - genetics ; Humans ; intraductal prostate cancer ; Loss of Heterozygosity ; Male ; Medical sciences ; Microsatellite Repeats - genetics ; Neoplasm Invasiveness ; Nephrology. Urinary tract diseases ; Prostatectomy ; Prostatic Intraepithelial Neoplasia - genetics ; Prostatic Intraepithelial Neoplasia - pathology ; Prostatic Intraepithelial Neoplasia - surgery ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2000-09, Vol.44 (4), p.265-270</ispartof><rights>Copyright © 2000 Wiley‐Liss, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4901-fce52775fc2b9d0e906e09fa32b7a638598412119aedaacebaddc400f79a1d333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F1097-0045%2820000901%2944%3A4%3C265%3A%3AAID-PROS1%3E3.0.CO%3B2-I$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F1097-0045%2820000901%2944%3A4%3C265%3A%3AAID-PROS1%3E3.0.CO%3B2-I$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1470861$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10951489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dawkins, Hugh J.S.</creatorcontrib><creatorcontrib>Sellner, Loryn N.</creatorcontrib><creatorcontrib>Turbett, Gavin R.</creatorcontrib><creatorcontrib>Thompson, Colin A.</creatorcontrib><creatorcontrib>Redmond, Sharon L.</creatorcontrib><creatorcontrib>McNeal, John E.</creatorcontrib><creatorcontrib>Cohen, Ronald J.</creatorcontrib><title>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression.
METHODS
IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer.
RESULTS
LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual.
CONCLUSIONS
Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.</description><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Alleles</subject><subject>Biological and medical sciences</subject><subject>cancer progression</subject><subject>Carcinoma, Intraductal, Noninfiltrating - genetics</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - surgery</subject><subject>Disease Progression</subject><subject>dysplasia</subject><subject>Genetic Markers - genetics</subject><subject>Humans</subject><subject>intraductal prostate cancer</subject><subject>Loss of Heterozygosity</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microsatellite Repeats - genetics</subject><subject>Neoplasm Invasiveness</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostatectomy</subject><subject>Prostatic Intraepithelial Neoplasia - genetics</subject><subject>Prostatic Intraepithelial Neoplasia - pathology</subject><subject>Prostatic Intraepithelial Neoplasia - surgery</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkt9u0zAUhyMEYmXwCsgXCHXSUmzHiZuCkKYURqSydgzE5ZHrnLSG_ClxstHn4gVxSClccINvIjm_851jf_a8mNEJo5S_YDSWPqUiHHPqVkzZmRAz8YpH4Wx2kc791YflDXsdTOgkWb7kfnrPGx1r7nsjyiX1BQvkiffI2i-UOirlD70TFwqZmMYj78fc2NZUujV1RdbY3iFWxFRto7JOt6ogWjXaVHWpSJ2Tdotk19S2VS2ScTpP_NXZOdmazdbfuAok2d7uCmWNIuNVeuX-qSpzuFu3dXssNZq4bFUf0eeks6bakLIuUHeFakipmq_Y2L6nVpXGpq_dNGitm_Ox9yBXhcUnh--p9-ntm4_JO3-xvEyTi4WvhbsqP9cYcinDXPN1nFGMaYQ0zlXA11JFwTSMp4JxxmKFmVIa1yrLtKA0l7FiWRAEp97zget6f-vQtlAaq7EoVIV1Z0EyGYk46oPXQ1C7A9oGc9g1xh1hD4xCbxJ6K9Bbgd8mQQgQ4EwCOJPwyyQEQCFZAofUMZ8emnfrErO_iIM6F3h2CCirVZE37p6M_ZMTkk4j5mI3Q-zOFLj_r8H-Ndew4aj-QHWvB78fqc4aRDKQIXy-uoTrKJA8iRbwPvgJutvV9w</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Dawkins, Hugh J.S.</creator><creator>Sellner, Loryn N.</creator><creator>Turbett, Gavin R.</creator><creator>Thompson, Colin A.</creator><creator>Redmond, Sharon L.</creator><creator>McNeal, John E.</creator><creator>Cohen, Ronald J.</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</title><author>Dawkins, Hugh J.S. ; Sellner, Loryn N. ; Turbett, Gavin R. ; Thompson, Colin A. ; Redmond, Sharon L. ; McNeal, John E. ; Cohen, Ronald J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4901-fce52775fc2b9d0e906e09fa32b7a638598412119aedaacebaddc400f79a1d333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Alleles</topic><topic>Biological and medical sciences</topic><topic>cancer progression</topic><topic>Carcinoma, Intraductal, Noninfiltrating - genetics</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - surgery</topic><topic>Disease Progression</topic><topic>dysplasia</topic><topic>Genetic Markers - genetics</topic><topic>Humans</topic><topic>intraductal prostate cancer</topic><topic>Loss of Heterozygosity</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microsatellite Repeats - genetics</topic><topic>Neoplasm Invasiveness</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostatectomy</topic><topic>Prostatic Intraepithelial Neoplasia - genetics</topic><topic>Prostatic Intraepithelial Neoplasia - pathology</topic><topic>Prostatic Intraepithelial Neoplasia - surgery</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dawkins, Hugh J.S.</creatorcontrib><creatorcontrib>Sellner, Loryn N.</creatorcontrib><creatorcontrib>Turbett, Gavin R.</creatorcontrib><creatorcontrib>Thompson, Colin A.</creatorcontrib><creatorcontrib>Redmond, Sharon L.</creatorcontrib><creatorcontrib>McNeal, John E.</creatorcontrib><creatorcontrib>Cohen, Ronald J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dawkins, Hugh J.S.</au><au>Sellner, Loryn N.</au><au>Turbett, Gavin R.</au><au>Thompson, Colin A.</au><au>Redmond, Sharon L.</au><au>McNeal, John E.</au><au>Cohen, Ronald J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>44</volume><issue>4</issue><spage>265</spage><epage>270</epage><pages>265-270</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
Prostate ducts and acini whose lumens are filled with malignant cells represent a well‐recognized histological pattern recently termed intraductal carcinoma of the prostate (IDC‐P). These tumors are often associated with rapid disease progression, and most recur after radical surgery. Controversy exists as to whether IDC‐P should be recognized as a separate entity, an extension of high‐grade dysplasia (PIN) or invasive carcinoma as described by the Gleason grading system. This study investigates the use of molecular markers in defining the position of IDC‐P in the evolutionary hierarchy of prostate cancer progression.
METHODS
IDC‐P, high‐grade dysplasia, and invasive cancers from a cohort of 20 selected radical prostatectomy specimens were screened for loss of heterozygosity (LOH), using 12 polymorphic microsatellite markers frequently lost in prostate cancer.
RESULTS
LOH was absent in Gleason grade 3 cancer, infrequent in high‐grade dysplasia (9%) and Gleason grade 4 cancer (29%), but common in IDC‐P (60%). In IDC‐P, and to a lesser extent Gleason grade 4 cancers, multiple sites of allelic loss in individual cases were usual.
CONCLUSIONS
Allelic instability provides further evidence that IDC‐P is not a simple extension of dysplasia, nor does it represent invasion of Gleason grade 3 cancers into the ductal/acinar system. IDC‐P and Gleason grade 4 cancer represent late but possibly separate events in prostate cancer evolution. Prostate 44:265–270, 2000. © 2000 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>10951489</pmid><doi>10.1002/1097-0045(20000901)44:4<265::AID-PROS1>3.0.CO;2-I</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-4137 |
ispartof | The Prostate, 2000-09, Vol.44 (4), p.265-270 |
issn | 0270-4137 1097-0045 |
language | eng |
recordid | cdi_proquest_miscellaneous_71764963 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma - surgery Alleles Biological and medical sciences cancer progression Carcinoma, Intraductal, Noninfiltrating - genetics Carcinoma, Intraductal, Noninfiltrating - pathology Carcinoma, Intraductal, Noninfiltrating - surgery Disease Progression dysplasia Genetic Markers - genetics Humans intraductal prostate cancer Loss of Heterozygosity Male Medical sciences Microsatellite Repeats - genetics Neoplasm Invasiveness Nephrology. Urinary tract diseases Prostatectomy Prostatic Intraepithelial Neoplasia - genetics Prostatic Intraepithelial Neoplasia - pathology Prostatic Intraepithelial Neoplasia - surgery Prostatic Neoplasms - genetics Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Tumors of the urinary system Urinary tract. Prostate gland |
title | Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A14%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinction%20between%20intraductal%20carcinoma%20of%20the%20prostate%20(IDC-P),%20high-grade%20dysplasia%20(PIN),%20and%20invasive%20prostatic%20adenocarcinoma,%20using%20molecular%20markers%20of%20cancer%20progression&rft.jtitle=The%20Prostate&rft.au=Dawkins,%20Hugh%20J.S.&rft.date=2000-09-01&rft.volume=44&rft.issue=4&rft.spage=265&rft.epage=270&rft.pages=265-270&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/1097-0045(20000901)44:4%3C265::AID-PROS1%3E3.0.CO;2-I&rft_dat=%3Cproquest_cross%3E71764963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71764963&rft_id=info:pmid/10951489&rfr_iscdi=true |